Cancer risk in rheumatoid arthritis patients treated with non-TNFi bDMARDs
Little is known about cancer risk in rheumatoid arthritis patients treated with non-TNFi bDMARDs. At this year’s SCR congress, Rasmus Westermann, a Ph.D. student at the Centre of Rheumatic Research in Aalborg, presented his recent study showing no significant increased risk of cancer risk in this group of patients. Let him elaborate in this MEDtalk.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.